摘要
目的探讨microRNA-155在初诊急性髓性血病(AML)患儿和非白血病对照儿童之间的差异表达情况,分析其意义。方法随机抽取我院标本库中自2012至2013年间收集的19例初诊AML骨髓标本以及20例非白血病对照儿童标本,利用Taqman探针实时荧光定量聚合酶链反应(qRT-PCR)法检测microRNA-155的相对表达水平(结果以2-△△Ct表示)。结果 microRNA-155的表达水平在AML患儿和对照组之间有显著差异(AML患儿组增高)(Z=-4.382;P=0.001);在预后分组中,不良组、中等组和良好组之间microRNA-155的表达水平无明显差异(P>0.05);在早期治疗反应分组中,缓解组和未缓解组之间表达水平无显著差异(P>0.05)。结论与对照组相比,microRNA-155在初诊小儿AML中发生显著的差异高表达现象,过表达的microRNA-155与危险度分组和早期治疗反应、预后等无显著相关性。microRNA-155有希望成为小儿AML的一个早期诊断标记物,但对于预后的意义尚有待于进一步的深入研究。
Objective To investigate the differential expression of microRNA-155 in new d^agnosed pedmtnc acute myeloid leukemia （AML） and its clinical significances. Methods 19 AML children and 20 non-leukemia controlled children were included. Real-time quantitative PCR （TaqMan）was applied to validate the expression of microRNA-155 in bone marrow samples. Results The expressions of microRNA-155 in AML children were significantly higher than those in controls （ P = 0. 001 ）. The levels of microRNA- 155 had no significant differences in Karyotype groups, response to treatment groups and risk groups （P 〉 0.05）. The microRNA-155 levels in AML childen were increased comparing with controls, but there were no distinctions in clinical groups associated with the outcome of disease. Conclusion The microRNA-155 may be used as one of biomarkers in the early diagnosis of childhood AML in the near future.
出处
《标记免疫分析与临床》
CAS
2014年第5期571-575,共5页
Labeled Immunoassays and Clinical Medicine
基金
国家自然科学基金(81170513
81370627)
